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Highlights: 
 Natural compounds represent an emerging class of therapeutics for skeletal diseases 
 Naringin exhibits pro-osteogenic and antiresorptive effects in preclinical studies 
 A thorough overview of naringin bioactivity in different bone disorders is provided 
 Controlled delivery of naringin in bone tissues holds an untapped potential 
Abbreviations: ROS, reactive oxygen species; CNS, central nervous system. 
Teaser: Naringin as a promising candidate for treating chronic bone diseases and promoting 
stem cell differentiation toward a pro-osteogenic phenotype. 
 
 
 
 
 
The use of natural compounds for treating chronic bone diseases holds remarkable 
potential. Among these therapeutics, naringin, a flavanone glycoside, represents one of the 
most promising candidates owing to its multifaceted effect on bone tissues. This review 
provides an up-to-date overview on naringin applications in the treatment of bone 
disorders, such as osteoporosis and osteoarthritis, and further highlights its potential for 
stem cell pro-osteogenic differentiation therapies. A critical perspective on naringin clinical 
translation is also provided. The topic is discussed in light of recently developed 
biomaterial-based approaches that potentiate its bioavailability and bioactivity. Overall, 
the reported pro-osteogenic, antiresorptive and antiadipogenic properties establish this 
flavanone as an exciting candidate for application in bone tissue engineering and 
regenerative medicine. 
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Introduction 
Currently, bone diseases and injuries represent a significant healthcare burden at a 
worldwide scale owing to the ineffectiveness of currently applied medical treatments for 
various skeletal disorders [1]. In fact, to date, a fully curative treatment for diseases such 
as osteoporosis, osteoarthritis, osteomyelitis or Paget’s disease has yet to be developed. 
Such a reality is further accentuated by critical-sized bone injuries that are unable to self-
regenerate [2]. For these cases, current strategies involve the use of bone grafts with 
embedded osteogenic growth factors to accelerate bone healing [2]. However, currently 
used osteogenic molecules are frequently associated with high production costs or 
deleterious side-effects limiting wide applicability and therapeutic efficacy [3]. In an effort 
to discover new approaches that increase the toolbox of effective treatments for bone 
pathologies, much focus has been put on the pursuit of natural-based products owing to 
their availability, cost-effectiveness and biological activity. 
Plant-based derivatives and marine-derived compounds represent one of the most cost-
effective sources of new bioactive molecules with promising therapeutic effects for 
different diseases including those of skeletal tissues [4]. In this context, various natural 
formulations (e.g., Drynaria fortunei or Erythrina variegata) have presented a remarkable 
potential for improving joint-related (e.g., osteoarthritis) osteoarticular degradation, or for 
treating bone injuries and bone-related disorders such as osteoporosis [4,5]. Typically, 
these formulations can modulate multiple signaling pathways and exert an effect in 
different cellular targets [6]. This is extremely valuable in the context of bone diseases 
considering their multifactorial pathogenesis, particularly in the case of osteoarthritis and 
osteoporosis [7]. In addition, their capacity for improving osteoporotic bone healing is 
highly related to its pro-osteogenic effect in osteoprogenitor cells as well as stem cells [4]. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
3 
 
Hence, research interest in this pro-osteogenic potential has been steadily growing for 
applications in stem-cell-based therapies for tissue engineering. 
Currently, the application for these natural small molecules in bone is particularly 
focused in the field of osteoporosis and on the pro-osteogenic differentiation of 
mesenchymal stromal stem cells. Such bioinspired approaches have recently shown 
promising pro-osteogenic potential for tissue engineering and regenerative medicine 
applications [4,8]. For example, a catechin-hydrate-coated substrate markedly enhanced 
the osteogenic differentiation and mineralization of hASCs [9]. In addition, catechin-coated 
polycaprolactone nanofiber scaffolds implanted in a critical-sized calvarial defect prompted 
a significant improvement in bone formation and density, as well as collagen deposition 
[9]. Another natural compound, icariin, a prenylated flavonol glycoside, has exhibited 
equally promising properties for bone tissue engineering [4]. In a mouse calvarial defect 
model, icariin was transplanted in calcium phosphate cement and resulted in enhanced 
bone and blood vessel formation [10]. Other in vivo studies have reported significant 
cartilage repair in mice bearing osteochondral defects, as well as bone formation and 
antiadipogenic behavior ameliorating osteoporotic status of ovariectomized mice [11,12]. 
In addition, resveratrol, formononetin and ginsenosides have all markedly improved in 
vivo bone formation and mineralization – in defect and ovariectomized animal models [4]. 
Also, oleanolic acid and green tea polyphenols have exhibited beneficial effects by reducing 
bone erosion and inflammation-induced bone loss in vivo [4,13]. Moreover, oral 
administration of quercetin-loaded solid lipid nanoparticles increased quercetin levels by 
3.5-fold of free drug and effectively reversed the osteoporotic status of ovariectomized rats 
to Sham levels [14]. Therefore, current research into natural small molecules suggests that 
they are a desirable source of potentially innovative pharmaceuticals. In the toolbox of 
naturally available compounds for treatment of bone disorders, naringin, a flavanone 
glycoside, is currently gathering special attention in preclinical studies and represents one 
of the most promising candidates for treating various bone diseases and promoting stem 
cell differentiation toward a pro-osteogenic phenotype. 
Naringin: a flavonoid with multiple therapeutic targets in bone tissues 
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Naringin, also known as naringenin 7-O-neohesperidose, is a natural flavonoid present in 
several fruits of the Citrus genus. Commercial grapefruit (Citrus paradisi) juice is the richest 
source of naringin (43.5 mg per 100 ml), where this compound is significantly more 
concentrated than in the hand-squeezed juice equivalent (23.0 mg per 100 ml) [15]. 
Similarly, industrial bergamot (Citrus bergamia) juice represents another valuable source 
of this compound, with naringin contents around 26.1 mg per 100 ml [15]. Furthermore, 
this compound is present in moderate quantities in Citrus aurantium (1.97 mg per ml) and 
even in certain bitter commercial orange juices (2.13 mg per 100 ml) [15]. In addition, 
naringin is also considered the main effective component in the basket fern Drynaria 
fortune – a traditional Chinese medicine for osteoporosis [16]. 
Naringin-enriched natural sources have been found to hold remarkable potential for 
various biomedical applications. In fact, Citrus paradisi juice has been described to increase 
the bioavailability of various drugs by decreasing first-pass metabolism, either via inhibition 
of cytochrome P450 (CYP)3A4 drug-metabolizing intestinal enzyme or by inhibiting the P-
glycoprotein-induced efflux from the enterocytes [17]. Industrial bergamot juice has also 
shown antiproliferative activity in human hepatocellular carcinoma (HepG2 cells) and plays 
a protective part in the treatment of rheumatoid arthritis owing to its antioxidant and anti-
inflammatory activity. Interestingly, it is also capable of mimicking the mechanism of 
statins, exerting significant hypolipidemic and hypocholesterolemic effects in humans [18–
20]. Naturally, these findings raised attention toward understanding the molecular effects 
of the main bioactives present in these sources, such as the flavanone naringin. Numerous 
preclinical studies investigating naringin bioactivity have since highlighted promising 
applications in different diseases (Figure 1) [16,21]. Among the different applications of 
naringin, recent research has focused on the pro-osteogenic effects of naringin in 
osteoporosis, or as a naturally inspired compound for directing mesenchymal stromal cell 
osteogenic differentiation. This unique biological activity in the context of bone disorders 
will be further discussed in the context of recent in vitro and in vivo preclinical reports. 
Preclinical in vitro studies 
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The pro-osteogenic effect of naringin is well described in the literature, suggesting 
potential applications as a bone therapeutic or as a mediator of mesenchymal stem cell 
(MSC) osteogenic lineage differentiation [16]. Different studies have shown that naringin 
has a significant effect on the proliferation or differentiation of osteoprogenitor cells such 
as murine pre-osteoblasts (MC3T3-E1) and cells with an osteoblastic phenotype, including 
human and murine primary fetal osteoblasts (hOB and pOB, respectively) [22,23]. Fan et 
al. found that naringin dose-dependently improved the proliferation of rabbit bone-
marrow-derived MSCs (BM-MSCs), and that naringin (1 µM) significantly increased the 
mRNA expression of osteocalcin (OC), alkaline phosphatase (ALP) and collagen type I (Col 
I) across studied time points (3, 7, 14, 21 days) [24]. Moreover, the authors observed that 
naringin improved the osteogenic commitment of cells by inhibiting peroxisome 
proliferator activated receptor (PPAR)γ expression, a key regulator in promoting MSC 
adipogenesis. The naringin-induced downregulation of PPARγ levels was linked to the 
corresponding upregulation of miR-20a expression [24]. In fact, the effect of naringin on 
the expression of the previous markers (OC and PPARγ) was effectively reversed by 
transfecting the BM-MSCs with anti-miR-20a antibody. Alternatively, in rat BM-MSCs, 
naringin increased the proliferation over 9 days in a dose-dependent manner (up to 10 
µg/ml) [25]. In these cells, the highest dose (100 µg/ml) was shown to decrease 
proliferation over long culture periods (9 days). After naringin treatment, there was a 5–7-
day delay before the ALP expression peak was observed, where the dose of 10 µg/ml 
exhibited the best osteogenic performance. These findings were supported by OC cell 
immunostaining after naringin treatment, in which 10 µg/ml led to the highest increase in 
OC expression (Figure 2a). Another study performed by Yu et al. further expands the 
knowledge regarding naringin-mediated activation of signaling pathways that are related 
to proliferation or osteogenesis [26]. These researchers found that naringin promotes rat 
BM-MSC osteogenesis via activation of the Notch signaling pathway [26]. Naringin 
significantly enhanced the mRNA levels of osteogenic markers [i.e., ALP, bone sialoprotein 
(BSP) and core-binding factor a1], whereas it decreased adipogenic regulator (PPARγ2) in a 
dose-dependent manner (Figure 2b). In addition, increased calcium node deposition in 
cultured cells also followed a dose-dependent behavior (Figure 2c). Interestingly, 
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treatment with the Notch inhibitor DAPT partly reduced naringin-induced ALP activity 
stimulation, calcium deposits and osteogenic mRNA transcript levels, whereas it 
suppressed the inhibitory effect on PPARγ2. Such findings strongly support the use of 
naringin as a pro-osteogenic natural compound. This is highly important in the context of 
stem-cell-based therapies because, currently, the main pharmaceutical approach has been 
the use of dexamethasone to guide lineage differentiation [27]. However, this 
glucocorticoid has been described to strongly induce adipogenesis even in an osteogenic 
medium, which can be counterproductive for optimizing the effectiveness of such therapies 
[28]. The described simultaneous antiadipogenic and osteogenic activity of naringin 
suggests a tremendous potential of this natural compound for stem-cell-based therapies. 
In the context of stem-cell-based bone therapies, the osteogenic effect of naringin was 
also assessed in human BM-MSCs. Zhang and his team observed a dose-dependent 
proliferative and osteogenic activity of naringin in human BM-MSCs up to 100 µg/ml [29]. 
The effect of the highest doses (10 and 100 µg/ml) on ALP activity was significant after only 
a 24 h incubation period and increased over 7 days. In addition, all naringin-treated groups 
exhibited a remarkable improvement in the expression of osteogenic markers ALP, OC, Col 
I and osteopontin (OPN) (Figure 2d). Moreover, Von Kossa staining of calcium nodes and 
ALP staining following naringin treatment further supported the dose-dependent effect of 
this flavonoid (Figure 2e). 
Numerous studies have investigated the role of different signaling pathways in 
determining the osteogenic activity of naringin in other cell types, such studies are 
important because different cell types can respond differently to the flavonoid [26,29,30]. 
Liu et al. found that naringin-induced osteogenic activity in human amniotic-fluid-derived 
stem cells (hAFSCs) was related to stimulation of the bone morphogenetic protein (BMP) 
and Wnt/β-catenin signaling pathways [31]. These pathways play a crucial part in 
osteogenesis regulation, adipogenesis repression and prevention of osteoblastic apoptosis 
[32]. Similar to previous studies, the authors demonstrated a dose-dependent increase in 
proliferative and osteogenic activities of this flavonoid (1–100 µg/ml), but not at the 
highest dose (200 µg/ml). Accordingly, calcium content after 28 days of naringin treatment 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
 
was markedly increased at 100 µg/ml. Reverse transcription PCR (RT-PCR) gene expression 
analysis of naringin-treated cells revealed significant upregulation of osteogenic marker 
genes (OPN and Col I) and a remarkable increase in osteoprotegerin (OPG) expression, once 
again suggesting a dual effect of naringin in promoting osteogenic proliferation and 
differentiation while inhibiting osteoclastogenesis. Interestingly, the expression levels of 
BMP-related regulators (RUNX2 and BMP-4), as well as Wnt-related genes (β-catenin and 
cyclin D1), were upregulated in naringin-treated cells, and the ALP activities were 
significantly reduced in the presence of inhibitors for these pathways (accordingly, noggin 
for BMP and DKK-1 for Wnt-signaling). 
Also, Pang et al. confirmed the significant osteogenic role of naringin in UMR 106 
osteoblast-like cells via estrogen receptor (ER)-dependent pathways [33]. Importantly, this 
study demonstrated that naringin exerts tissue-selective estrogenic effects on bone and 
possibly in adipose tissue, but not in the uterus. It was proposed that this selective behavior 
is determined by differential phosphorylation of ERα and ERE-dependent transcriptional 
activity. In addition, the authors observed that naringin (10 nM) markedly enhanced OPG 
mRNA expression, and that this effect was reversed in the presence of an ER-antagonist 
(ICI 182780). OPG secretion is linked to inhibition of osteoclastogenesis, which suggests a 
potential antiresorptive capacity of naringin. In fact, besides its known pro-osteogenic 
effect, naringin has been demonstrated to be capable of inhibiting bone resorption in vitro 
via osteoclasts [30,34]. In this case, the anti-inflammatory effect of naringin appears to play 
a part in its antiresorptive activities. This is supported by OPG and nuclear factor (NF)-κB 
pathway involvement in osteoclastogenesis [5]. 
In this context, Ang et al. observed that naringin inhibits osteoclastogenesis and bone 
resorption by suppressing RANKL-induced NF-κB activation and phosphorylation of 
extracellular receptor kinase (ERK) [30]. Notably, the flavonoid was able to reduce the bone 
resorption area while maintaining the cell number of osteoclast-like cells (Figure 3a,b). It is 
also worth noting that murine macrophage RAW 264.7 cells, which were used to generate 
osteoclast-like cells, showed a remarkable tolerance against naringin dosages, with only 
10% apoptosis after a 24 h treatment with 1 mM of naringin (~580 µg/ml). Nevertheless, 
another study achieved significant bone resorption inhibition at much lower dosages of the 
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flavonoid [34]. In this study, Xu et al. [34] investigated the naringin effect in repressing 
osteoclastogenesis of a rat calvarial bone culture, after incubation with different naringin 
doses (1, 10 and 100 mg/l). The tartrate-resistant alkaline phosphatase (TRAP) staining of 
osteoclasts after treatment with different naringin doses for 10 days revealed a dose-
dependent inhibition of osteoclastogenesis (Figure 3c). Moreover, naringin markedly 
suppressed osteoclastogenesis in a time-dependent manner, from 1 to 10 days of in vitro 
2D culture (Figure 3d). After incubation with different naringin concentrations, the authors 
observed a 74% (100 mg/l), 52% (10 mg/l) and 41% (1 mg/l) reduction in the number of 
TRAP-stained osteoclasts. 
The above findings demonstrate that naringin is capable of significantly repressing 
osteoclastogenesis and reducing bone resorption areas. This is an important finding for 
applications in bone-degenerative disorders, such as post-menopausal osteoporosis, 
characterized with osteolytic degradation as a result of markedly increased bone turnover. 
Taken together, the preclinical in vitro studies highlight a tremendous potential for naringin 
applications as a bone therapeutic and for committing stem cells into the osteoblastic 
lineage. 
Preclinical in vivo studies 
The above examples provide an important body of knowledge regarding the potential of 
naringin for treating different bone disorders. Adding to this, various in vivo studies that 
will be discussed in the following paragraphs provide further evidence of the realistic 
potential of naringin to be used as a therapeutic alternative in the foreseeable future. 
Naringin has improved overall bone health in healthy and gonadectomized animal models 
(such as rat and mouse) in vivo. In healthy mice, naringin daily oral administration 
significantly enhanced femoral bone mass by increasing trabecular and cortical bone [35]. 
In another study in healthy mice, Yin et al. achieved the first validation of successful stem-
cell-based therapy involving naringin for improving bone formation in vivo. Initially, human 
periodontal dental ligament stem cells (hPDLSCs) were seeded in a nanohydroxyapatite 
scaffold and cultured in naringin-containing (1 µM) medium for 1 week before implantation 
into healthy mice. The transplant was harvested 8 weeks later and the naringin-treated 
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group exhibited improved trabecular bone maturity surrounding the scaffold, as well as a 
locally increased OPN and OC expression by 50% [36]. 
Currently, most in vivo studies involving naringin have been performed in 
ovariectomized mice. Pang et al. demonstrated that treatment of ovariectomized mice with 
naringin (200 and 400 mg/kg per day) for 6 weeks significantly improved bone quality at 
the distal femur, proximal tibia and lumbar spine [33]. In addition, naringin suppressed the 
ovariectomized-induced increase in urinary calcium excretion as well as losses in bone mass 
and strength. However, in this study, naringin treatment failed to significantly decrease 
urinary deoxypyridoline levels in ovariectomized mice – a collagen degradation product 
that reflects bone resorption rate. In another study, ovariectomized mice were treated 
daily with various naringin doses (60, 300 and 1500 mg/kg) via oral gavage, leading to 
effective recovery of ovariectomized-induced bone loss [25]. The authors found that 
naringin at 300 mg/kg provided an optimal increase in bone mass density (BMD), bone 
volume as well as trabecular thickness, while decreasing trabecular space. Furthermore, 
naringin treatment did not change the uterus weight significantly, suggesting that naringin 
did not elicit off-target estrogenic effects. Interestingly, a study by Sun et al. investigated 
the effect of a combination regimen of oral naringin (300 mg/kg) with treadmill exercise in 
ovariectomized rats for 60 days [37]. Authors found that a naringin + exercise regimen led 
to stronger effects on osteoporosis than either as a monotherapy on bone mass 
preservation and improved bone strength (Figure 4a). In a different report, Wang et al. 
observed an improved bone strength in ovariectomized mice even at lower doses (5 mg/kg) 
of naringin (Figure 4bi) [38]. This dose markedly improved ALP, RUNX2 and Col I expression 
in vivo (Figure 4bii). In particular, the authors observed that co-administration of AMPK and 
Akt inhibitors partly reversed naringin effects in vivo, suggesting that the osteogenic activity 
of this flavonoid is in part via its stimulation of the Wnt/β-catenin signaling upon interaction 
with AMPK and Akt. Moreover, ovariectomized mice achieved equally increased cell 
proliferation when treated with naringin or conventional parathyroid hormone, but 
naringin-treated mice were characterized with the highest enhancement in ALP activity 
(Figure 4biii). Adding to this evident potential, a recent study found that naringin (100 and 
200 mg/kg) significantly inhibited the ovariectomized-induced reduction in bone marrow 
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microvessels, regulating the function of endothelial cells while promoting angiogenesis in 
bone (Figure 4c) [39]. In parallel, oral administration of naringin (300 mg/kg) has recently 
been shown to augment the vascularization of the callus in osteoporotic fractures in 
ovariectomized rats, by significantly improving the expression of vascular endothelial factor 
(VEGF) and VEGFR-2 [40]. This led to an increase in vessel numbers and thickness, as well 
as larger neovascularization areas. Overall, this strategy resulted in accelerated bone 
healing at 2, 4 and 8 weeks post-fracture in a dose-dependent manner (40, 100 and 300 
mg/kg). The development of bone vasculature is particularly relevant for the treatment of 
osteoporosis but also in the context of tissue engineering and regenerative medicine [41]. 
In particular, angiogenesis is fundamental for engineering a clinically relevant sized tissue, 
which requires a vascular network for properly supplying cells beyond the diffusional limit 
for oxygen and nutrients [42]. These findings regarding the proangiogenic activity of 
naringin are supported by the previous in vitro study demonstrating naringin-induced 
osteogenic differentiation of BM-MSCs via activation of the Notch signaling pathway [26]. 
Endothelial Notch activity plays a key part in simultaneously promoting bone angiogenesis 
and osteogenesis and, therefore, could be one of the main mechanisms behind the 
osteoprotective effect of naringin [43]. 
Alternatively, other animal models support the above findings regarding the clinical 
potential of naringin in improving bone health status. Wei et al. demonstrated the 
antiosteoporotic activity of naringin in a retinoic-acid-induced osteoporosis rat model [44]. 
Naringin treatment with different doses (20, 40, 100 mg/kg) led to improvements in bone 
weight index, length and diameter of the femur bone, as well as bone ash content and 
levels of calcium and phosphorus. In orchidectomized rats, treatment with naringin at 200 
ppm for 2 months significantly increased serum insulin-like growth factor (IGF)-I, femoral 
bone density and calcium content, as well as suppressed plasma TRAP activity, associated 
with bone resorption [45]. Alternatively, subcutaneously administered naringin (10 mg/kg) 
is also described to promote bone formation in a titanium-particle-induced diabetic murine 
calvarial osteolytic model [46]. Moreover, naringin embedded in a collagen bone graft also 
promoted bone formation in a rabbit bone defect model [47]. 
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Naringin exhibited the most therapeutic potential in disuse-induced osteoporosis animal 
models, caused by mechanical unloading and characteristic in bedridden or low-mobility 
patients, as well as astronauts [48]. A study by Ma et al. investigated naringin treatment in 
denervated bone induced by sciatic neurectomy [49]. Disuse-induced bone loss in rats was 
induced by sciatic neurectomy, resulting in reduced BMD and trabecular microarchitecture 
in the distal femur, as well as increased urinary deoxypyridoline levels. The authors 
confirmed the dose-dependent (30, 100, 300 mg/kg) recovery induced by naringin 
treatment in restoring trabecular microarchitecture as well as bone formation rates to 
Sham levels (Figure 5a). Moreover, the highest naringin dose had a profound effect in 
improving osteogenesis and inhibiting osteoclastogenesis in vivo, as indicated by OC and 
TRAP immunohistochemistry analysis in the distal femoral metaphysis (Figure 5b), as well 
as reducing urinary deoxypyridoline. Naringin treatment also successfully prevented 
biomechanical deterioration of the ipsilateral femur in immobilized rats (Figure 5b). This 
protective effect is thought to be modulated via naringin-induced increase in Semaphorin 
3A expression in vivo, a local factor of the bone microenvironment that simultaneously 
promotes bone formation while reducing bone resorption [49]. However, Semaphorin 3A 
deficiency is directly implicated in the disruption of bone remodeling and subsequent bone 
loss in diabetic rats [50]. This might explain why naringin successfully prevented bone loss 
in a rat model of streptozotocin-induced diabetes [51]. Considering this, these studies 
suggest that naringin could be a promising therapeutic alternative in treating disuse 
osteoporosis and for improving bone health in patients with diabetes mellitus type 1. 
Naringin has also shown particular promise in treating osteoarticular degenerative 
diseases, such as osteoarthritis, ankylosis spondylitis and autoimmune arthritis. In such 
disorders, the characteristic destruction of inflamed cartilage tissue significantly affects the 
surrounding bone tissues and heavily impairs patient quality of life. Naringin was used in a 
recent study that involved a mouse model of ankylosis spondylitis. Analysis of harvested 
tissues showed that flavonoid intraperitoneal administration attenuated the expression of 
proinflammatory cytokines [such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and 
IL-6] and inhibited the production of signal transducer and activator of transcription 
(STAT)3 and Janus kinase (JAK)2 (implicated in the sensitivity to this disease) in a dose-
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
dependent manner [52]. In parallel, naringin also improved oxidative stress markers in 
treated mice by restoring the activity of superoxide dismutase, catalase and glutathione 
peroxidase in vivo. Recently, orally administered naringin has also shown remarkable 
potential in preventing cartilage destruction in surgically and monosodium-iodoacetate-
induced osteoarthritis models in vivo [53,54]. In these studies, naringin has been reported 
to improve the weight-bearing ability of osteoarthritic rats, as well as inhibit key enzymatic 
mediators of osteoarthritis progression [such as matrix metalloproteinase (MMP)-13 and 
ADAMTS-5] in affected mice. In addition, some studies link the antiarthritic activity of 
naringin to the regulation of inflammatory proteins and cell mediators responsible for 
facilitating joint cellular infiltration [55,56]. Indeed, in a mouse model of autoimmune 
arthritis, naringin was able to modulate T regulatory cells and significantly upregulated IL-
4 expression, which is described to ameliorate cartilage proteoglycan depletion induced by 
proinflammatory cytokines [55]. Moreover, in a collagen-induced arthritis mouse model, 
naringin oral treatment significantly mitigated intercondylar knee-joint damage, pannus 
formation and synovium infiltration [56]. 
These studies highlight the potential of naringin for therapeutic applications in 
osteoarticular degenerative diseases, yet there are still few studies in the literature 
exploring this promising phytotherapeutic alternative. In fact, beyond the classic anti-
inflammatory and antioxidant activities implicated in the therapeutic potential of this 
flavanone in osteoarthritis, there are other interesting targets such as ERs that are currently 
linked to osteoarthritis and rheumatoid arthritis therapeutic alternatives [57,58]. As 
explained earlier, the interaction between naringin and ERs is well explored in the context 
of osteoporotic scenarios, but this is still undervalued in the context of osteoarticular 
therapies.  
Overall, the above preclinical studies provide significant evidence for naringin 
multifactorial osteostimulative and chondroprotective effects, either in bone-fracture 
healing or for bone erosive and osteoarticular degenerative disorders. However, so far, 
naringin has been mostly explored for treating bone-degenerative disorders. It is worth 
noting that bone remodeling is a product of concomitant interaction between bone 
formation and resorption, meaning that disruption of this balance leads to bone 
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dysfunction [49]. In this context, clinically available therapeutics such as antiresorptive 
bisphosphonates and anabolic parathyroid hormone can reduce bone formation and 
promote bone resorption, respectively, which might explain why combination therapy 
approaches between clinical therapeutics or with mechanical loading have been 
investigated with the aim of improving bone quality [59,60]. Furthermore, long-term disuse 
osteoporosis has been described as less sensitive to bisphosphonate treatment than other 
types of osteoporosis [61]. Alternatively, bone formation is significantly reduced with 
ageing, mostly attributed to a shift from osteogenesis to predominant adipogenesis in the 
marrow stroma, leading to senile osteoporosis [62]. Naringin treatment could aid in 
revascularizing the affected skeletal sites and, ultimately, rejuvenate this 
microenvironment to a healthier phenotype. Taken together, the simultaneous 
antiresorptive, osteostimulative and antiadipogenic role of naringin ultimately improve 
bone health and establish this flavonoid as a valuable candidate for pursuing alternative 
clinical treatment options for some of the most common bone disorders or injuries due to 
fractures. 
Current obstacles in naringin clinical translation 
Despite its promise for therapeutic action in several pathologies, in particular for 
preventing degenerative diseases and improving bone health status, naringin is yet to be 
approved for clinical administration, either as a single therapy or in combination with other 
bioactives. This fact is mainly correlated with the extensive in vivo metabolism of 
flavonoids, a crucial factor that limits their therapeutic efficacy [63]. In addition, naringin 
exhibits low bioavailability (8.8%) following oral administration owing to its poor water 
solubility and dissolution rates [64,65]. In fact, the poor water solubility of naringin is 
considered the rate-limiting step for its absorption in the body, thus leading to inferior 
therapeutic efficacy [65]. Moreover, this drug is extensively degraded in acidic pH and 
enzymatically cleaved by β-glucosidases in the gut, inherent to the intestinal microflora 
[66]. 
The effects of naringin have been mainly explored via oral absorption; however, its 
absorption in the gastrointestinal tract is slow and irregular [67]. Moreover, the intestinal 
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microbiota plays a crucial part in defining the bioavailability of flavonoids such as naringin. 
It is important to emphasize that this microbiome is characterized by substantial 
interindividual heterogeneity; hence, ultimately, the microbiome defines the clinical 
efficacy of dietary flavonoids [63]. On account of these limitations, recently there have 
been some in vitro attempts for improving flavonoid bioavailability and absorption, by 
increasing solubility and dissolution rates, as well as protection from intestinal degradation 
upon encapsulation in nanoparticles, microparticles or water-soluble fibers [65,67–69]. It 
has been suggested that minimal absorption rates of such drugs can severely restrict their 
clinical applications [14]. 
Adding to this, naringin can also be degraded during blood circulation if administered 
intravenously. Indeed, flavonoids such as naringin, are unstable during circulation and 
easily undergo oxidation in serum and in the liver, where they are generally degraded by 
hepatic β-glucosidases [66]. It is also reported that naringin spontaneously interacts with 
BSA under physiological conditions, an aspect that can play a major part in defining its 
pharmacokinetic profile, facilitating excretion and hence influencing its bioavailability [70]. 
This parameter is also influenced by the decreased solubility of flavanones under 
physiological conditions (pH = 7.4), owing to degradation into chalcone structures [65]. Yet, 
so far, no attempts have been made toward formulating oral or intravenously 
administrable nanocarriers for the controlled delivery of naringin to skeletal sites. As 
recognized from previously highlighted studies with other natural compounds (e.g., 
quercetin), controlled delivery via nanocarriers can significantly improve their in vivo 
therapeutic effect [14]. There have been some recent developments concerning the 
formulation of naringin within suitable carriers for oral absorption, but research is still at 
an early stage and studies are yet to validate this approach in vivo. Concerning the 
parenteral route of administration, relevant literature remains scarce and there is a great 
untapped potential to be exploited for this approach. 
Nanotechnology-based drug delivery systems enable the improvement of solubility, 
bioavailability and pharmacokinetics of entrapped pharmaceutics, protecting them from 
degradation and unspecific interactions while prolonging their circulation times [71,72]. 
Furthermore, these nanocarriers can provide a sustained release profile and can be 
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modified with specific targeting moieties for improving accumulation at the desired 
locations [73]. Hence, the bioavailability of naringin could be vastly improved by inclusion 
in a nanocarrier, ultimately leading to locally increased concentrations in the bone 
microenvironment. Recognizing the potential of nanotechnology for flavonoid delivery, the 
following chapter will explore current approaches in the literature concerning the 
incorporation of naringin within biomaterial-based nano- or micro-platforms for potential 
skeletal delivery. 
Biomaterial-based platforms for naringin incorporation 
As mentioned, naringin has a low bioavailability and undergoes extensive metabolism in 
vivo. This has motivated researchers to explore biomaterial-based platforms for 
immobilizing or protecting naringin from degradation, and for achieving a sustained 
spatiotemporally controlled release with the aim of improving its therapeutic effect. 
Regarding the production of naringin–biomaterial hybrids, Ji et al. incorporated the 
flavanone within an electrospun nanoscaffold comprising polycaprolactone (PCL) and 
poly(ethylene glycol)-b-polycaprolactone (PEG-b-PCL) nanofibers (~242 nm) to serve as a 
bone-regenerating implant [74]. PCL-PEG-b-PCL-naringin nanoscaffolds elicited an 
increased MC3T3-E1 proliferation, as well as enhanced osteogenic differentiation 
(evaluated via ALP activity) after 14 days of culture in medium with no osteogenic 
supplements. Moreover, for cells cultured in these nanoscaffolds, Alizarin Red S staining 
showed improved calcium mineralization nodules after only 10 days. In addition, the 
authors studied the effect of the naringin nanoscaffold in suppressing osteoclastogenesis 
in a critical size defect model of mouse calvarial bone. After 14 days of implantation, the 
defects treated with PCL-PEG-b-PCL-naringin nanoscaffolds showed a significant decrease 
in TRAP staining when compared with treatment with blank PCL nanoscaffolds. These 
results corroborate naringin-induced osteoclastogenesis suppression and suggest potential 
applications of this drug-loaded nanofiber scaffold in bone tissue engineering. Regarding 
this application, Chen et al. developed a porous biodegradable composite comprising 
genipin-crosslinked gelatin and β-Ca3(PO4)2 ceramic microparticles (GGT) mixed with 
naringin (10 mg/ml). These composites were formulated with the aim of enhancing bone 
repair in vivo in a rabbit calvarial defect model [75]. The obtained radiographic analysis and 
AC
CE
PT
ED
 M
AN
US
CR
IPT
16 
 
histological hematoxylin and eosin (H&E) staining revealed that, 8 weeks post-
implantation, naringin-loaded GGT composites promoted a significant deposition of new 
bone formation when compared with GGT controls. Moreover, complete osseointegration 
of the biodegradable implant could be readily observed, with newly formed bone replacing 
a significant amount of the naringin-loaded GGT composites. 
Recently, Guo et al. developed a porous poly(L-lactide) (PLLA) scaffold incorporating the 
anti-inflammatory drug parthenolide and spray-dried naringin-loaded chitosan 
microspheres embedded in the matrix [76]. The regenerative performance of this dual drug 
delivery scaffold was studied in a rat model of periodontal fenestration defects. Analysis of 
µCT data revealed that, 8 weeks post-implantation, the dual delivery scaffold significantly 
enhanced bone volume and decreased inflammatory response in the defect, when 
compared with the PLLA group. Histological H&E analysis corroborated the superior 
performance of the dual delivery scaffold in improving periodontal tissue regeneration. 
Also, IL-6 immunostaining showed that the dual delivery scaffold achieved the least 
number of positive staining areas for the cytokine, highlighting its anti-inflammatory 
activity. The authors therefore suggested a possible application as an adjuvant for the 
treatment of periodontitis. However, it should be noted that MC3T3-E1 cell proliferation 
assays showed that the dual delivery scaffold and the parthenolide-loaded group 
significantly decreased cell proliferation in comparison with the naringin-loaded group. 
These results suggest that this flavanone can partially rescue the observed cytotoxic effect 
of the anti-inflammatory drug parthenolide. 
In parallel, Chang et al. recently developed a naringin-loaded (0.85%) pH-responsive 
hydrogel for periodontitis treatment, taking advantage of the characteristic pH reduction 
hallmark in inflammation sites [77]. In this study, the authors formulated a hydrogel 
comprising carboxymethyl-hexanoyl chitosan, β-glycerophosphate and glycerol via a 
thermally induced sol-to-gel transition. Notably, the hydrogel underwent instant sol-to-gel 
transition at 37ºC. Interestingly, a twofold higher amount of naringin was released in acidic 
conditions (pH = 5.5) when compared with physiological conditions (pH = 7.4), accordingly 
51% versus 24% of total naringin released in the first 4 h. Here, a silk-induced acute 
periodontitis mouse model was used to evaluate the hydrogel biological performance. The 
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naringin-loaded hydrogel markedly attenuated local inflammation and periodontal 
breakdown after 7 days. Gene expression analysis also showed a remarkable 
downregulation of Toll-like receptor 2, TNF-α and RAGE expression, but not myd88, which 
is why the authors suggested that this therapeutic activity might be achieved via a LPS-
mediated myd88-independent mechanism. 
Yu et al. developed a mineralized collagen coating with embedded naringin-loaded 
metal-organic frameworks (MOFs) [78]. By taking advantage of the inherent antimicrobial 
and pro-osteogenic activities of this flavanone, the authors aimed to design a 
multifunctional osseointegrating orthopedic coating. The collagen-MOF-naringin coating 
significantly improved MSC cell adhesion over other control groups. Moreover, RT-PCR 
analysis of several osteogenic gene markers at 14 days of culture on different coating 
substrates showed improved expression of Col I, OC and RUNX2 for the collagen-MOF-
naringin group. In addition, Alizarin Red S staining indicated that this coating led to the 
highest MSC mineralization after 21 days of culture. Furthermore, the promising osteogenic 
activity of the collagen-MOF-naringin coating is complemented with enhanced 
antibacterial activity against Staphylococcus aureus at 3, 5 and 7 days of culture in 
comparison to other coating groups. 
Alternatively, Feng et al. developed naringin-loaded water-soluble ternary nanoparticles 
comprising amylose, α-linoleic acid and β-lactoglobulin as a delivery platform [79]. As 
determined by HPLC, these carriers exhibited high naringin encapsulation efficiency (79.7 
±4.2%) and could inspire further studies aiming to improve naringin bioavailability using 
food-grade formulations. Moreover, naringin has also been entrapped within different 
spray-dried microparticles (e.g., gastro-resistant cellulose acetate phthalate and 
maltodextrin) with the aim of improving its dissolution rates and bioavailability upon oral 
delivery [67,68]. More recently, other studies focused on the incorporation of naringin in 
different nanocarriers, either as a stabilizing agent with gum tragacanth in gold 
nanoparticles or by studying its inclusion complex with food-grade β-cyclodextrin [69,80]. 
Overall, these studies suggest promising future applications for naringin delivered 
through biomaterials. Yet, so far, delivery of naringin to skeletal sites has been mostly 
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explored in the context of impregnation in implantable porous composites, polymeric 
scaffolds or in surface coatings [74–76,78]. Apart from such examples, no study has 
described the in vivo performance of naringin-loaded delivery systems. It is undoubtedly 
crucial to investigate whether incorporating naringin within such nano- and micro-carriers 
can augment this flavonoid bioactivity in different diseases. In addition, different bone 
disorders are characterized by specific pathophysiological conditions that represent unique 
exploitable opportunities for nanocarriers endowed with stimuli-responsiveness [81]. 
Harnessing such biological triggers to our advantage could further improve the current 
potential of bone therapeutics that are either synthetically or naturally available. 
Concluding remarks and future perspectives 
The search for safer and more-suitable osteoinductive agents has led researchers to 
explore the potential of natural-based compounds such as naringin. As highlighted by the 
numerous preclinical studies investigating the therapeutic activities of this flavanone, there 
is unquestionable potential in naringin application for bone diseases or for instructing stem 
cell osteogenic differentiation. Indeed, naringin has shown promise for applications in 
skeletal disorders for which current pharmaceutic strategies are lacking, also providing a 
relatively safe option for osteoinduction, particularly when compared with other 
commonly used osteoinductive drugs. The studies involving the loading and controlled 
release of this flavanone are emerging and their outcome could pave the way for future 
biomedical applications. This could potentially lead to the establishment of natural-derived 
products as valuable sources for new pharmaceutics that find application in cell-based 
therapies for tissue engineering and regenerative medicine. 
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Figure legends 
Figure 1. Overview of various conditions in which naringin has been described to display protective and 
therapeutic effects. For a more general description of the activity of naringin in these conditions, see [21]. 
Figure 2. Naringin increases the expression of osteogenic markers, leading to enhanced mineralization. (a) 
osteocalcin (OC) immunostaining of rat BM-MSCs after induction with different naringin doses for 6 days, 
(ai) control, (aii) 1 µg/ml, (aiii) 10 µg/ml. (b) RT-PCR gene expression analysis of osteogenic markers after a 
14-day treatment of rat BM-MSCs with different naringin doses. Data are represented in mean ± s.d. (n = 5). 
aP<0.05 versus control group; bP<0.05 versus the OIM group; cP<0.01 versus the 1 µg/ml group; dP<0.01 
versus the 10 µg/ml. (c) Alizarin Red S staining of calcium deposits formed in rat BM-MSCs after incubation 
with various doses of naringin (1, 10 and 50 µg/ml) for 21 days. (d) RT-PCR gene expression analysis of 
osteogenic markers after a 7-day treatment of human BM-MSCs with different naringin doses. Data represented 
in mean ± s.d. (n = 6). *P<0.05 and **P<0.01 compared with the control group (n = 6). (e) ALP staining of 
human BM-MSCs 7 days after drug administration. Adapted, with permission, from [25,29]; also, with 
permission, from [26]. 
Figure 3. Naringin effectively inhibits bone resorption in vitro. (a) Representative scanning electron 
microscopy (SEM) micrographs of bone resorption pits induced by osteoclast-like cells in bovine bone slices 
after incubation with different naringin doses (0, 0.5 and 1 mM) for 24 h. (b) Total resorption pit areas of each 
treatment group as measured under SEM. (c) Microscopic view of TRAP-stained osteoclasts in calvarial bone 
cultures treated with different doses of naringin for 10 days. (d) Number of TRAP-stained osteoclast cells 
treated with different doses of naringin for 1, 3,7 and 10 days. *P<0.05; **P<0.01; ***P<0.001. All data above 
are represented in mean ± s.d. (n = 3). Adapted, with permission, from [30] and [34]. 
Figure 4. Pro-osteogenic and proangiogenic protective activities of naringin in vivo. (a) 3D reconstruction of 
trabecular microarchitecture within the distal femoral metaphyseal region in Sham, ovariectomized (OVX), 
naringin (NG) or exercise (EX) monotherapy or combination regimen groups. (bi) Optimal naringin-induced 
osteogenic gene (ALP, RUNX2, Col I) expression at 5 mg/kg (n = 5). *P<0.05; **P<0.01; ***P<0.001 
compared to control group. (bii, biii) Naringin-induced (5 mg/kg) increase in ALP activity and osteoblastic 
cell proliferation. Data represented in mean ± SEM (n = 5 and n = 3, respectively). #P<0.05; ##P<0.01 
compared with the OVX group. (c) Naringin markedly inhibited (100 mg/kg) the OVX-induced reduction in 
bone marrow microvessels (black arrows). Adapted, with permission, from [37] and [38] and [39]. 
Figure 5. Naringin therapeutic activity in disuse osteoporosis induced by unilateral sciatic neurectomy (USN). 
(a) Representative 3D images showing the trabecular microarchitecture in the distal femoral metaphysis of 
each group. (b) Immunohistochemical staining of OC and osteoclasts (TRAP+) in the distal femoral 
metaphysis, as well as histomorphometric analysis of naringin-prevented deterioration of the ipsilateral femur 
as a result of immobilization. Adapted, with permission, from [49]. 
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